<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474757</url>
  </required_header>
  <id_info>
    <org_study_id>20104</org_study_id>
    <nct_id>NCT03474757</nct_id>
  </id_info>
  <brief_title>Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases</brief_title>
  <acronym>TREND</acronym>
  <official_title>Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases - TREND Colombia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This population-based descriptive study will characterize first-time users of three NOACs
      (rivaroxaban, dabigatran and apixaban) in prevention of stroke in non-valvular atrial
      fibrillation (SPAF) patients and will assess the patterns of drug utilization in routine
      general practice in Colombia
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sex</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-morbidity</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Healthcare utilization</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Primary Care Physicians visits, Outpatient visits and Hospital admissions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Naive to non-naive patient</measure>
    <time_frame>At Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose at first prescription</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Switch to another study drug</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time trends of usage of study medications</measure>
    <time_frame>Up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">10528</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>SPAF patients in Colombia_Rivaroxaban</arm_group_label>
    <description>First time users of rivaroxaban in the Audifarma database</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPAF patients in Colombia_Dabigatran</arm_group_label>
    <description>First time users of dabigatran in the Audifarma database</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPAF patients in Colombia_Apixaban</arm_group_label>
    <description>First time users of apixaban in the Audifarma database</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data Collection</intervention_name>
    <description>Data will be extracted from July 2009 to the last available database extraction</description>
    <arm_group_label>SPAF patients in Colombia_Rivaroxaban</arm_group_label>
    <arm_group_label>SPAF patients in Colombia_Dabigatran</arm_group_label>
    <arm_group_label>SPAF patients in Colombia_Apixaban</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Using the population from the Audifarma database, the study will be comprised of three
        separate cohorts of first time users of rivaroxaban, dabigatran and apixaban using the
        first prescription date (index date) of the respective drug (index drug). All patients aged
        ≥18 years with at least one year of enrollment in the databases and one year since first
        encounter with healthcare provider will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First prescription of NOACs (rivaroxaban, dabigatran and apixaban) in the outpatient
             setting.

          -  Non valvular Atrial Fibrillation (NVAF) Patients

          -  aged ≥18 years

          -  at least one year of enrollment in the Audifarma database

          -  one year since first encounter with healthcare provider will be included in the study

        Exclusion Criteria:

          -  Patients with any record of index drug prescription prior to the enrolment period.

          -  Patients who qualify as members of more than one cohort study on the same day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

